Pharmacotherapy for Dementia & Alzheimer's Disease: Essential CGP Certified Geriatric Pharmacist Exam Prep

Introduction: Navigating Dementia Pharmacotherapy for the CGP Exam

As an expert pharmacy education writer for PharmacyCert.com, we understand the critical importance of mastering geriatric pharmacotherapy. One of the most challenging yet essential areas for any pharmacist, especially those preparing for the Complete CGP Certified Geriatric Pharmacist Guide, is the pharmacotherapy for dementia and Alzheimer's Disease. With an aging global population, the prevalence of dementia continues to rise, making it a cornerstone of geriatric practice. The CGP exam rigorously tests a candidate's ability to apply evidence-based pharmacotherapy principles to complex geriatric cases, and dementia management is frequently a central theme.

Dementia is an umbrella term for a group of symptoms affecting cognitive functions like memory, reasoning, and communication, severe enough to interfere with daily life. Alzheimer's disease (AD) is the most common cause of dementia, accounting for 60-80% of cases. Other forms include vascular dementia, Lewy body dementia, and frontotemporal dementia. As a certified geriatric pharmacist, your role extends beyond simply knowing drug names; it encompasses understanding the nuances of diagnosis, treatment goals, patient-specific considerations, managing challenging behavioral symptoms, and navigating the ethical complexities inherent in caring for this vulnerable population. This mini-article will equip you with the focused knowledge needed to excel on this critical topic for the CGP exam as of April 2026.

Key Concepts in Dementia and Alzheimer's Disease Pharmacotherapy

Understanding the pathophysiology, drug mechanisms, indications, side effects, and monitoring is paramount for the CGP exam. Here's a breakdown:

1. Cholinesterase Inhibitors (ChEIs)

• Drugs: Donepezil (Aricept), Rivastigmine (Exelon, Exelon Patch), Galantamine (Razadyne).
• Mechanism of Action (MOA): These drugs inhibit acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the synaptic cleft. By doing so, they increase the availability of acetylcholine, a neurotransmitter critical for memory, learning, and other cognitive functions, which is deficient in AD. Rivastigmine also inhibits butyrylcholinesterase.
• Indications: Primarily indicated for mild to moderate Alzheimer's disease. Donepezil is also approved for severe AD.
• Dosing & Administration:
  • Donepezil: Oral, once daily. Available in ODT. Start low (5mg) and titrate up (10mg, or 23mg for severe AD) to minimize GI side effects.
  • Rivastigmine: Oral capsules (twice daily) or transdermal patch (once daily). Patch often preferred for better tolerability and adherence. Start low and titrate.
  • Galantamine: Oral solution, immediate-release tablets (twice daily), or extended-release capsules (once daily). Start low and titrate.
• Side Effects: Primarily dose-dependent cholinergic side effects: nausea, vomiting, diarrhea, anorexia, bradycardia, syncope, insomnia, vivid dreams. The patch formulation of rivastigmine can reduce GI side effects.
• Clinical Pearls: Consider dose adjustments in renal/hepatic impairment. Avoid concomitant use with anticholinergic medications, as they can antagonize the effects of ChEIs.

2. NMDA Receptor Antagonist

• Drug: Memantine (Namenda, Namenda XR).
• Mechanism of Action (MOA): Memantine is a non-competitive NMDA receptor antagonist. It blocks the effects of abnormal excitatory glutamatergic neurotransmission, which is thought to contribute to neuronal dysfunction and death in AD. It does not interfere with normal physiological activation of NMDA receptors.
• Indications: Moderate to severe Alzheimer's disease.
• Dosing & Administration: Oral, once daily (XR) or twice daily (IR). Start low (5mg) and titrate up (to 10mg BID or 28mg XR) to minimize dizziness and confusion.
• Side Effects: Generally well-tolerated. Common side effects include dizziness, headache, confusion, and constipation.
• Clinical Pearls: Often used in combination with a cholinesterase inhibitor for moderate to severe AD. Dose adjustment is required for severe renal impairment.

3. Newer Amyloid-Beta Targeting Monoclonal Antibodies

As of April 2026, these agents represent a significant shift in AD treatment by targeting underlying pathology rather than just symptoms.

• Drugs: Lecanemab (Leqembi), Donanemab (expected approval). Aducanumab (Aduhelm) was the first but has seen limited uptake.
• Mechanism of Action (MOA): These drugs are monoclonal antibodies that bind to and facilitate the clearance of amyloid-beta plaques from the brain, a hallmark of Alzheimer's pathology. They aim to slow disease progression rather than just manage symptoms.
• Indications: Patients with early Alzheimer's disease (mild cognitive impairment or mild dementia stage) with confirmed amyloid pathology. This typically requires amyloid PET imaging or CSF testing.
• Administration: Intravenous infusions, typically every two to four weeks.
• Side Effects: The most significant concern is Amyloid-Related Imaging Abnormalities (ARIA), which can manifest as ARIA-E (edema/effusion) or ARIA-H (microhemorrhages/hemosiderosis). ARIA is often asymptomatic but can cause headache, confusion, dizziness, visual disturbances, or gait disturbance. Regular MRI monitoring is crucial. Other side effects can include infusion-related reactions.
• Clinical Pearls: Requires careful patient selection, specialized diagnostic testing, and rigorous monitoring. Pharmacists play a vital role in patient education, ensuring adherence to infusion schedules, and recognizing potential ARIA symptoms. Patients on anticoagulants may have an increased risk of intracerebral hemorrhage.

4. Pharmacological Management of Behavioral and Psychological Symptoms of Dementia (BPSD)

BPSD includes agitation, aggression, psychosis, depression, anxiety, and sleep disturbances. The CGP exam will emphasize a structured approach:

• First-Line: Non-Pharmacological Interventions: Always prioritize these! Environmental modifications, behavioral strategies, individualized activities, caregiver education, addressing unmet needs (pain, hunger, thirst, toileting), and sensory stimulation.
• Pharmacological Interventions (Use with Extreme Caution):
  • Atypical Antipsychotics (e.g., Risperidone, Olanzapine, Quetiapine, Aripiprazole): May be used for severe, persistent agitation, aggression, or psychosis that is dangerous to the patient or others and unresponsive to non-pharmacological interventions. All carry a Black Box Warning for increased risk of mortality and cerebrovascular events in elderly patients with dementia-related psychosis. Start low, go slow, and use for the shortest duration possible.
  • Antidepressants (e.g., SSRIs like Citalopram, Sertraline): May be used for depression or anxiety. Citalopram has shown some efficacy for agitation but carries a risk of QT prolongation.
  • Mood Stabilizers (e.g., Valproic Acid): Generally not recommended for BPSD due to limited efficacy and significant side effects, but may be considered in specific cases of bipolar disorder or seizure history.
  • Benzodiazepines (e.g., Lorazepam): Generally discouraged due to risks of sedation, increased falls, paradoxical disinhibition, and cognitive impairment. Only for acute, severe agitation or anxiety when other options fail, for very short durations.
  • Other Agents: Prazosin (for agitation), Cannabinoids (limited evidence, specific cases).

5. Non-Pharmacological Strategies

These are the bedrock of dementia care and often the first-line approach for many symptoms. They include cognitive stimulation therapy, exercise, music therapy, reminiscence therapy, validation therapy, bright light therapy, and addressing environmental triggers.

How It Appears on the Exam: CGP Certified Geriatric Pharmacist Practice Questions

The CGP exam will test your comprehensive understanding of dementia pharmacotherapy through various question formats, often within a case-study framework. Expect questions that require you to:

• Differentiate between drug classes: Understand the unique MOA, indications, and side effect profiles of ChEIs, memantine, and the newer amyloid-targeting agents.
• Apply therapy to specific stages of AD: Recommend appropriate initial therapy based on whether the patient has mild, moderate, or severe AD, or early AD with confirmed amyloid pathology.
• Manage side effects: Identify common and severe adverse drug reactions and propose strategies for mitigation or management. For example, knowing that rivastigmine patch might reduce GI upset compared to oral forms.
• Identify drug interactions: Recognize clinically significant interactions, such as anticholinergics with ChEIs, or specific risks with newer agents (e.g., ARIA risk with APOE4 carriers).
• Recommend non-pharmacological interventions: For BPSD, be prepared to prioritize and articulate appropriate non-drug strategies before considering pharmacotherapy.
• Dosing adjustments: Apply knowledge of renal and hepatic impairment to adjust medication dosages.
• Monitor efficacy and safety: Understand what parameters to monitor for each drug (e.g., cognitive assessments for efficacy, MRI for ARIA, vital signs for bradycardia).
• Deprescribing: Identify situations where medication discontinuation is appropriate, considering patient goals, advanced disease, or intolerable side effects.
• Ethical considerations: Questions may touch on informed consent for newer therapies, capacity for decision-making, or balancing quality of life with disease modification.

For a deeper dive into common exam question styles, consider reviewing CGP Certified Geriatric Pharmacist practice questions and taking advantage of free practice questions available on PharmacyCert.com.

Study Tips for Mastering This Topic

To confidently tackle dementia pharmacotherapy on the CGP exam, consider these strategies:

1. Create Drug Tables: For each medication (donepezil, rivastigmine, galantamine, memantine, lecanemab, donanemab, relevant antipsychotics), create a table summarizing:
   • Mechanism of Action
   • Indications (specific stage of AD)
   • Common Side Effects
   • Serious Side Effects/Black Box Warnings
   • Dosing and Administration Pearls (e.g., titration, patch vs. oral, renal/hepatic adjustment)
   • Key Drug Interactions
   • Monitoring Parameters
2. Focus on Case Studies: Practice applying your knowledge to realistic patient scenarios. Think about a patient presenting with new memory loss, or an agitated patient with moderate AD. What would be your step-by-step approach?
3. Understand "Why": Don't just memorize recommendations. Understand the rationale behind starting low and titrating slow, prioritizing non-pharmacological interventions for BPSD, or the risks associated with certain drug classes in the elderly.
4. Review Guidelines: Familiarize yourself with current guidelines from organizations like the Alzheimer's Association, American Geriatrics Society (AGS) Beers Criteria (for medications to avoid or use with caution), and clinical practice guidelines for dementia management.
5. Stay Updated: Especially for newer therapies like the amyloid-beta targeting agents, be aware of their latest approval status, specific patient criteria, and monitoring requirements as of April 2026.
6. Practice Questions: Regularly test your knowledge with practice questions. This helps solidify concepts and identifies areas needing further review.

Common Mistakes to Watch Out For

Avoid these common pitfalls that can lead to incorrect answers on the CGP exam:

• Over-reliance on Pharmacotherapy for BPSD: Failing to recommend or prioritize non-pharmacological interventions for behavioral symptoms is a significant error.
• Ignoring Drug Interactions: Prescribing an anticholinergic concurrently with a cholinesterase inhibitor, or not considering the increased risk of hemorrhage with newer amyloid-targeting agents in patients on anticoagulants.
• Incorrect Staging for Therapy: Recommending a ChEI for severe AD as initial monotherapy (when memantine or combination is more appropriate), or an amyloid-targeting agent for advanced AD.
• Missing Renal/Hepatic Adjustments: Forgetting to adjust doses for drugs like memantine or cholinesterase inhibitors in patients with impaired kidney or liver function.
• Neglecting Side Effect Management: Not identifying or addressing common side effects like bradycardia with ChEIs or dizziness with memantine.
• Lack of Awareness of Newer Agents' Specifics: Not knowing the strict criteria for initiation (e.g., confirmed amyloid pathology, early AD) or the critical monitoring for ARIA with lecanemab/donanemab.
• Failing to Consider Deprescribing: Continuing medications without clear benefit in advanced dementia or when risks outweigh benefits.

Quick Review / Summary

Pharmacotherapy for dementia and Alzheimer's disease is a cornerstone of geriatric pharmacy practice and a high-yield topic for the CGP exam. Remember these key takeaways:

• Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine) are for mild to moderate AD, increasing acetylcholine. Watch for cholinergic side effects.
• Memantine is an NMDA receptor antagonist for moderate to severe AD, reducing glutamatergic overstimulation. Generally well-tolerated.
• Newer Amyloid-Beta Targeting Monoclonal Antibodies (Lecanemab, Donanemab) are for early AD with confirmed amyloid, aiming to slow progression. Rigorous monitoring for ARIA is essential.
• BPSD Management: Always start with non-pharmacological interventions. Pharmacotherapy (e.g., atypical antipsychotics) carries significant risks and should be used cautiously, at the lowest effective dose, for the shortest duration.
• Pharmacist's Role: Crucial in optimizing therapy, managing side effects, patient and caregiver education, monitoring, and deprescribing.
• Exam Focus: Expect case-based questions on drug selection, side effect management, drug interactions, non-pharmacological strategies, and ethical considerations.

Mastering this complex area not only prepares you for the CGP exam but also empowers you to make a profound difference in the lives of patients and families affected by dementia. Keep practicing, stay current, and approach each scenario with a patient-centered mindset.